Evidence map›Paper›PMID 34483988›Full record

ArticleFrontiers in psychiatry2021

Metabolomic Biomarkers Are Associated With Area of the Pons in Fragile X Premutation Carriers at Risk for Developing FXTAS.

Marwa Zafarullah, Blythe Durbin-Johnson, Emily S Fourie, David R Hessl, Susan M Rivera, Flora Tassone

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marwa ZafarullahDepartment of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, CA, United States.
Blythe Durbin-JohnsonDivision of Biostatistics, School of Medicine, University of California, Davis, Davis, CA, United States.
Emily S FourieCenter for Mind and Brain, University of California, Davis, Davis, CA, United States.
David R HesslMIND Institute, University of California, Davis Medical Center, Sacramento, CA, United States.
Susan M RiveraCenter for Mind and Brain, University of California, Davis, Davis, CA, United States.
Flora TassoneDepartment of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, CA, United States.
University of California, Davis · USUniversity of California Davis Medical Center · US

Funding

Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01MH078041 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HESSL, DAVID R, RIVERA, SUSAN M · 2007 to 2017
$5.4M
Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01NS110100 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAVID R HESSL, Susan M Rivera · 2018 to 2026
$5.4M
NIMH NIH HHS R01 MH078041NINDS NIH HHS R01 NS110100
6 · The paper itself

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late adult-onset neurodegenerative disorder that affects movement and cognition in male and female carriers of a premutation allele (55-200 CGG repeats; PM) in the fragile X mental retardation (

Indexed as

area of the ponsbrain measuresfragile X-associated tremor/ataxia syndromelipidsmetabolic biomarkerspremutation carriers

Identifiers

PMID34483988
PMCPMC8415564
OpenAlexW3195249294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.